Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: The present disclosure relates to compounds of Formula (I) and (II): and pharmaceutically acceptable salts and isotopically labeled derivatives thereof, wherein X1, X2, R1, R2, R3, R4, R5, R6A, R6B and R7 are as defined herein, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I) and (II): and pharmaceutically acceptable salts and isotopically labeled derivatives thereof, wherein X1, X2, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I) and (II): and pharmaceutically acceptable salts and/or isotopically labeled derivatives thereof, wherein X1, X2, RA, y, R3, R4, R5, R6, R7, a and b are as defined herein, and Ring A2 is a 6-membered heteroaryl ring, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I), (II), and (III): and pharmaceutically acceptable salts, tautomers, and/or isotopically labeled derivatives thereof, wherein X1, X2, RA, y, R3, R4, R5, R6, R7, R6A, R6B, a and b are as defined herein, and Ring A2 is a monocyclic pyrazolyl ring, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I) or (III). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I) and (II): and pharmaceutically acceptable salts, tautomers, and/or isotopically labeled derivatives thereof, wherein X1, X2, RA, y, R3, R4, R5, R6, R7, a and b are as defined herein, and Ring A2 is a 5-membered heteroaryl ring, provided the heteroaryl ring is not pyrazolyl, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.

Abstract: The present disclosure relates to compound of Formula (I), such as compounds of Formula (II), (III), and (IV), useful for cGAS modulation, wherein L1, R1, R2, R9, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, Y, and r are described therein.

Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables Y1-Y6, X, Z, Z1, Z2, R2-R3, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables Y1-Y6, X, Z, Z1, Z2, R2-R3, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. The compounds have sodium channel blocking activity that are useful for treating sodium channel-mediated diseases, in particular for treating pain.

Abstract: The present disclosure relates to compounds of Formula (I): (I), wherein Ring A, R1, R2, R3, and m are described herein. The present disclosure relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes, or tautomers thereof, in the treatment of cGAS-related diseases and disorders.

Abstract: The present disclosure relates to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutical compositions comprising the same, methods of preparation, and methods of use and treatment, e.g., as inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.